Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection

The Activate study

Datos Bibliográficos

ID14907431
AutoresJ Grebely (0000-0002-1833-2017, UNSW Sydney, autor de correspondencia), Olav Dalgard (0000-0003-4470-3181, Oslo University Hospital), Evan B Cunningham (0000-0002-8048-3473, UNSW Sydney), Behzad Hajarizadeh (0000-0003-2212-2028, UNSW Sydney), Graham R Foster (0000-0002-3704-386X, Queen Mary University of London), Philip Bruggmann (0000-0002-0436-8895, Addiction Switzerland), Brian Conway (0000-0001-6821-7829, Vancouver Infectious Diseases Centre), Markus Backmund (Ludwig-Maximilians-Universität München), Geert Robaeys (Universitair Ziekenhuis Leuven), Tracy Swan (0000-0002-9399-3659, Hepatitis B Foundation), Janaki Amin (0000-0003-2161-9366, UNSW Sydney), Philippa S Marks, Philippa Marks (0000-0003-0480-1203, UNSW Sydney), Sophie Quiene (UNSW Sydney), Tanya Applegate (0000-0002-8657-4261, UNSW Sydney), Tanya L Applegate, Michelle Weltman (0000-0002-1677-7653, Nepean Hospital), Martin Weltman, David Shaw (0000-0001-8180-6927, Royal Adelaide Hospital), Adrian J Dunlop (0000-0003-2394-5966, University of Newcastle Australia), Adrian Dunlop, Margaret Hellard (0000-0002-5055-3266, Burnet Institute), Julie Bruneau (0000-0002-3484-6456, Centre Hospitalier de l’Université de Montréal), Håvard Midgard (0000-0001-5043-5107, Oslo University Hospital), Stefan Bourgeois (Ziekenhuisnetwerk Antwerpen Stuivenberg), Cornelia Staehelin (0000-0002-1733-7051, University of Bern), Gregory J Dore (0000-0002-4741-2622, UNSW Sydney)
Año2017
Volumen47
Páginas177-186
Fecha de publicación2017-09-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaInternational Journal of Drug Policy (JOURNAL)
Identificadores de la revistaISSN: 0955-3959 • E-ISSN: 1873-4758
EditorialElsevier BV (PUBLISHER)
DOI10.1016/j.drugpo.2017.05.020
PMID28624134
OpenAlexW2625414995
IdiomaEN
Citas recibidas4
Referencias citadas35